Financial reports
ARS
2023 FY
Annual report to shareholders
26 Apr 24
10-K
2023 FY
Annual report
11 Mar 24
10-Q
2023 Q3
Quarterly report
7 Nov 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
10-Q
2023 Q1
Quarterly report
9 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
10-K
2022 FY
Annual report
9 Mar 23
10-Q
2022 Q3
Quarterly report
8 Nov 22
10-Q
2022 Q2
Quarterly report
9 Aug 22
10-Q
2022 Q1
Quarterly report
9 May 22
Current reports
8-K
Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update
11 Mar 24
8-K
Olema Oncology JP Morgan Conference January 2024
8 Jan 24
8-K
Olema Oncology Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate
8 Jan 24
8-K
Entry into a Material Definitive Agreement
5 Jan 24
8-K
Regulation FD Disclosure
6 Dec 23
8-K
Olema Oncology Announces Palazestrant Demonstrates Attractive Combinability with CDK4/6 Inhibitors Ribociclib and Palbociclib in Phase 1b/2 Studies
5 Dec 23
8-K
Olema Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update
7 Nov 23
8-K
Olema Oncology Announces Positive Phase 2 Monotherapy Clinical Study Results for Palazestrant
23 Oct 23
8-K/A
Olema Oncology Appoints Oncology Biotech Executive Scott Garland to Board of Directors
18 Oct 23
8-K
Olema Oncology Appoints Oncology Biotech Executive Scott Garland to Board of Directors
17 Oct 23
Registration and prospectus
S-8
Registration of securities for employees
11 Mar 24
424B3
Prospectus supplement
12 Feb 24
S-3
Shelf registration
31 Jan 24
424B5
Prospectus supplement for primary offering
5 Jan 24
D
$130.00 mm in equity, sold $130.00 mm, 12 investors
14 Sep 23
424B5
Prospectus supplement for primary offering
9 Mar 23
S-8
Registration of securities for employees
9 Mar 23
S-3
Shelf registration
28 Feb 22
S-8
Registration of securities for employees
28 Feb 22
S-8
Registration of securities for employees
17 Mar 21
Proxies
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
DEFA14A
Additional proxy soliciting materials
28 Apr 22
DEF 14A
Definitive proxy
28 Apr 22
DEFA14A
Additional proxy soliciting materials
27 Apr 21
DEF 14A
Definitive proxy
27 Apr 21
Other
EFFECT
Notice of effectiveness
12 Feb 24
UPLOAD
Letter from SEC
7 Feb 24
CORRESP
Correspondence with SEC
7 Feb 24
EFFECT
Notice of effectiveness
3 May 22
CORRESP
Correspondence with SEC
28 Apr 22
UPLOAD
Letter from SEC
4 Mar 22
EFFECT
Notice of effectiveness
19 Nov 20
CERT
Certification of approval for exchange listing
18 Nov 20
SEC STAFF
SEC staff action: Order
17 Nov 20
CORRESP
Correspondence with SEC
16 Nov 20
Ownership
4
Cyrus Harmon
29 Mar 24
144
Notice of proposed sale of securities
28 Mar 24
SC 13G
Deep Track Capital, LP
22 Mar 24
4
Naseem Zojwalla
20 Mar 24
4
ANDREW RAPPAPORT
6 Mar 24
4
Cyrus Harmon
4 Mar 24
144
Notice of proposed sale of securities
29 Feb 24
SC 13G/A
Paradigm Biocapital Advisors LP
14 Feb 24
SC 13G/A
Cormorant Asset Management, LP
14 Feb 24
SC 13G/A
Kynam Capital Management, LP
14 Feb 24